Predict your next investment

Other

See what CB Insights has to offer

Investments

5

Portfolio Exits

2

About Epiphron Capital

Epiphron Capital (益普资本) is a cross-border, healthcare-focused investment fund.

Epiphron Capital Headquarter Location

China

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Epiphron Capital News

YishengBio Raises $130M in Series B Funding

Mar 2, 2021

YishengBio Co., Ltd., a Beijing, China-based fully integrated biopharmaceutical company, closed a US$130m Series B funding round.After completing the Series B funding round, the company’s institutional investors include: OrbiMed, Oceanpine, EightRoad, F-Prime Capital, 3W Capital, Hillhouse Capital, Adjuvant Capital, MSA Capital, AIHC, Epiphron Capital, Superstring Capital, Haitong International, etc.YishengBio’s YSJA™ rabies vaccine is the first alum-free lyophilized rabies vaccine launched in China.The rabies vaccine has been commercialized in China and has served over 16 million patients for post-exposure protection against rabies.Being able to accelerate post-exposure immune protection,PIKA rabies vaccine has the potential to lead in the rabies vaccines market in the future. Disclaimer: This story is auto-aggregated & summarized by a computer program and has not been created by StartupAround.

Epiphron Capital Investments

5 Investments

Epiphron Capital has made 5 investments. Their latest investment was in Clarapath as part of their Series B on November 11, 2021.

CBI Logo

Epiphron Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/17/2021

Series B

Clarapath

$32M

Yes

1

6/1/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

1/8/2020

Series B

Subscribe to see more

$99M

Subscribe to see more

10

1/2/2019

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Other Investors

Subscribe to see more

Subscribe to see more

10

Date

11/17/2021

6/1/2021

1/8/2020

1/2/2019

Round

Series B

Series C

Series B

Series B

Other Investors

Company

Clarapath

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$32M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

10

10

Epiphron Capital Portfolio Exits

2 Portfolio Exits

Epiphron Capital has 2 portfolio exits. Their latest portfolio exit was Transcenta Holding on September 29, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/29/2021

IPO

2

3/20/2020

IPO

Subscribe to see more

Subscribe to see more

10

Date

9/29/2021

3/20/2020

Exit

IPO

IPO

Companies

Subscribe to see more

Valuation

Acquirer

Subscribe to see more

Sources

2

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.